FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Mem­bers of an FDA ad­vi­so­ry com­mit­tee were not asked to vote Thurs­day on As­traZeneca’s an­ti­co­ag­u­lant re­ver­sal drug An­dexxa, but they did raise sev­er­al safe­ty and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.